Great Tree Pharmacy Co (6469) Fair Value & Analysis
Healthcare · TW · Market cap 11.5B TWD
Fair value as of: Jun 24, 2026
Analysis
Great Tree Pharmacy Co (6469) currently trades at 74.10 TWD, while our model-based Fair Value estimate is 84.09 TWD — implying the stock looks roughly 13.5% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Great Tree Pharmacy Co., Ltd. engages in medicines, health food, maternal and infant products, and cosmetics businesses in Taiwan, Mainland China, and Malaysia. It provides drug procurement services, as well as acts as an agent for various clinics, joint clinics, and community health centers. The company is also involved in selling food and beverages, and daily necessities; cleaning supplies; wholesale and retail of cosmetics, and other goods; cargo sorting, packaging, and warehousing; retail sale of animal medicines and ornamental animals; fish and pet food retail; medical equipment and pet-related products; wholesale of precision instruments; development and retail business; biotechnology; investment business, and specific specialized zones businesses. In addition, it provides technical services; management consultants, residential and building properties; development, leasing, rental, and sales of real estate; property leasing; industrial plant development; biotechnology research…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Great Tree Pharmacy Co (6469) undervalued?
What is the fair value of 6469?
What is the quality score of 6469?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.